A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Latest Information Update: 22 May 2026
At a glance
- Drugs Tovecimig (Primary) ; Paclitaxel
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms COMPANION-002
- Sponsors Compass Therapeutics
Most Recent Events
- 07 May 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 07 May 2026 Planned primary completion date changed from 1 Jul 2025 to 1 Dec 2026.
- 07 May 2026 Status changed to active, no longer recruiting.